Wealth Enhancement Advisory Services’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-42,090
Closed -$38.7K – 4338
2026
Q2
$38.7K Buy
42,090
+11,631
+38% +$11K ﹤0.01% 3955
2026
Q1
$27.7K Buy
30,459
+13,535
+80% +$16.4K ﹤0.01% 3482
2025
Q4
$21.5K Sell
16,924
-3,820
-18% -$5.13K ﹤0.01% 3584
2025
Q3
$27K Buy
20,744
+388
+2% +$508 ﹤0.01% 3488
2025
Q2
$27.5K Buy
20,356
+106
+0.5% +$118 ﹤0.01% 3275
2025
Q1
$21.9K Buy
+20,250
New +$28.4K ﹤0.01% 2910
2024
Q4
– Sell
-10,197
Closed -$19.7K – 3048
2024
Q3
$19.7K Buy
+10,197
New +$20K ﹤0.01% 2667

Other funds holding LAB

Wealth Enhancement Advisory Services's LAB Position: Q3 2026 in Review

Wealth Enhancement Advisory Services sold out of Standard BioTools (LAB) in Q3 2026, closing a stake of 42,090 shares — an estimated $38.7K sold.

Wealth Enhancement Advisory Services first reported a position in LAB in Q3 2024 and held it in 7 quarters. The position peaked at $38.7K in Q2 2026. 104 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

  • Wealth Enhancement Advisory Services reported no remaining Standard BioTools position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 42,090 Standard BioTools shares in Q3 2026, an estimated $38.7K.
  • Wealth Enhancement Advisory Services first reported a position in Standard BioTools in Q3 2024 and held it in 7 quarters.
  • Wealth Enhancement Advisory Services's Standard BioTools position peaked at $38.7K in Q2 2026.
  • 104 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.